Is Hyperglycemia a Causal Factor in Cardiovascular Disease?

Does proving this relationship really matter? Yes

Christopher G. Parkin, MS
Jaime A. Davidson, MD, FACE

Given that cardiovascular disease is a common complication of diabetes (1) and the leading cause of death among people with diabetes (2,3), it is important that we use the most effective therapies to manage lipids, blood pressure, and glycemia to reduce the risk, progression, and impact of macrovascular disease. Recent studies by Gaede et al. (4) clearly demonstrated that intensive management of all risk factors, including lipids, blood pressure, and glycemia, had significant beneficial effects on cardiovascular-related deaths. This intensive therapy was also found to be cost-effective (5).

Nevertheless, questions are now being raised regarding the importance of glycemia relevant to the prevention and/or progression of cardiovascular disease. To begin answering these questions, we first need to ask: Is there any reason not to believe there is a link between hyperglycemia and cardiovascular disease?

PLENTY OF AVAILABLE EVIDENCE — We have strong evidence from large randomized controlled trials that clearly establish a causal relationship between poor glycemic control and the development of microvascular disease (6,7). Why should we assume that large blood vessels are immune to the same damaging effect of hyperglycemia? We should not: there is plenty of evidence linking hyperglycemia to macrovascular risk.

Analysis of data from 3,642 U.K. Prospective Diabetes Study subjects (for whom complete data for potential confounders were available) showed a significant 14% (P < 0.0001) reduction in myocardial infarction for each 1% reduction in mean A1C (8).

An early meta-regression analysis by Coutinho et al. (9) showed that the progressive relationship between glucose levels and cardiovascular risk extends below the diabetic threshold. Analyzed studies comprised 95,783 people who had 3,707 cardiovascular events over 12.4 years.

More recently, Levitan et al. (10) confirmed that hyperglycemia in the nondiabetic range was associated with increased risk of fatal and nonfatal cardiovascular disease, with a similar relationship between events and fasting or 2-h plasma glucose. In the meta-analysis of 38 studies, cardiovascular events increased in a linear fashion without a threshold for 2-h postprandial plasma glucose, whereas fasting plasma glucose showed a possible threshold effect at 99 mg/dl.

Hanefeld et al. (11) found significant positive trends in risk reduction for all selected cardiovascular event categories with treatment with acarbose, an α-glucosidase inhibitor that specifically reduces postprandial plasma glucose excursions by delaying the breakdown of disaccharides and polysaccharides (starches) into glucose in the upper small intestine. In all of the seven studies with at least 1 year’s duration, people treated with acarbose not only showed reduced 2-h postprandial levels compared with control subjects, but treatment with acarbose was significantly associated with a reduced risk for myocardial infarction and other cardiovascular events. Similar findings have been reported in subjects with impaired glucose tolerance who were treated with acarbose (12).

A 2006 meta-analysis by Stettler et al. (13) showed that efforts to improve glycemia yield significant reductions in macrovascular disease in type 1 and type 2 diabetes. The benefit was particularly strong in younger patients with shorter duration of the disease. A more recent report from the Euro Heart Survey on Diabetes and the Heart (14) showed a pronounced decrease in cardiovascular events in subjects with newly diagnosed diabetes treated with glucose-lowering agents.

The International Diabetes Federation recently published its guideline for managing postprandial glucose (15), providing strong evidence regarding the role of postprandial hyperglycemia as an independent risk factor for macrovascular disease. Among the several studies cited in the guideline is a report by Esposito et al. (16), who demonstrated a reduction in carotid intima-media thickening by reducing postprandial glucose excursions. Carotid intima-media thickening is directly related to clinical manifest cardiovascular disease and is associated with increased risk for myocardial infarction and stroke (17,18).

Although the exact mechanism by which vascular damage occurs is not fully understood, numerous studies support the hypothesis of a causal relationship between hyperglycemia and oxidative stress (19–24). Oxidative stress has been implicated as the underlying cause of both the macrovascular and microvascular complications associated with type 2 diabetes (25–27).

Some propose that hyperglycemia, free fatty acids, and insulin resistance feed into oxidative stress, protein kinase C activation, and advanced glycation end product receptor activation, leading to vasoconstriction, inflammation, and thrombosis (28). Acute hyperglycemia and glycemic variability appear to play important roles in this mechanism. For example, some studies (29–31) have shown that variability in glucose levels may be
Is hyperglycemia a causal factor in CVD?

more damaging than a constant high concentration of glucose.

Regardless of the mechanism(s) behind vascular damage, or whether you even believe there is a relationship between hyperglycemia and cardiovascular disease, perhaps the bigger question is, “Does it really matter?”

FROM EVIDENCE-BASED TO SOUND CLINICAL JUDGMENT — Of course it is important to understand as much as we can about diabetes, its causes, and its complications. However, to debate whether hyperglycemia is a causal factor in the development of cardiovascular disease serves little purpose. Almost everyone agrees that hyperglycemia drives the development and progression of microvascular complications. Therefore, we should continue to treat hyperglycemia aggressively, even though some believe that we lack randomized control trials (the alleged “holy grail” of research) to prove a relationship between hyperglycemia and macrovascular disease.

It is important to note, however, that although the Diabetes Control and Complications Trial (DCCT) (6) failed to show a statistically significant causal relationship between hyperglycemia and cardiovascular disease because of the low rate of macrovascular events, the DCCT/Epidemiology of Diabetes Interventions and Complications (EDIC) (32) study, which followed 1,341 of the original DCCT cohort for an additional 12 years, showed that intensive management of glycemia does have significant long-term effects on the risk of cardiovascular disease in type 1 diabetes. Whereas some may argue that the EDIC study was not randomized, and thus not substantive, it can also be argued that EDIC was simply an extension of DCCT, with long enough duration to actually detect the impact of glycemic control on macrovascular disease.

If the question at hand is whether we should stop treating the other risk factors, lipids and high blood pressure, and focus only on glucose control, then a serious debate would be warranted. To our knowledge, no such therapeutic approach has been proposed.

In summary, our position is that there is strong evidence supporting the causal relationship between hyperglycemia and cardiovascular disease. It is also our position that diabetes and all of its associated risk factors should be managed aggressively, regardless of whether one believes in the current strength of the evidence relationship between hyperglycemia and cardiovascular disease.

Clearly, sound clinical judgment is needed to set safe and reasonable goals for diabetes management, especially in elderly patients and those with known cardiovascular disease or other high-risk factors; however, in our younger patients, aggressive treatment of all metabolic abnormalities with persistent titration of medication until all goals are met is needed.

Regarding the significance of this particular debate, we find it somewhat concerning that both the American Diabetes Association and the American Heart Association has actually spent time researching and reviewing this issue (33). We propose that more time and effort be spent on finding ways to improve our delivery of care rather than focus on academic issues that have no real clinical bearing on the way we manage diabetes.

Acknowledgments — No potential conflicts of interest relevant to this article were reported.

References
1. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmeichel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577–1583
2. Niskanen L, Turpeinen A, Penttula I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 1998;21:1861–1869
3. Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002;155:714–719.
4. Gaede P, Lund-Andersen H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–591
5. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: Results and projections from the steno-2 study. Diabetes Care 2008;31:1510–1515
6. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): prospective observational study. BMJ 2000;320:405–412
8. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;320:405–412
9. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233–240
10. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147–2155
11. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper T, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35:1073–1078
12. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–494
13. Stettler C, Allemand S, Juni P, Cull CA, Holman RR, Egger M, Krahenbuhl S, Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27–38
14. Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2008;29:177–184
15. International Diabetes Federation Guideline Development Committee. Guideline for management of postmeal glucose (article online). 2007. Available from www.idf.org
16. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214–219
17. Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, Heiss G. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995;26:386–391

18. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wollson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14–22

19. Ceriello A, Falleti E, Motz E, Taboga C, Tonutti L, Ezsol Z, Gonano F, Bartoli E. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998;30:146–149

20. Cominacini L, Fratta PA, Garbin U, Camagnola M, Davoli A, Rigoni A, Zenti MG, Pastorino AM, Lo CV. E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress. Diabetologia 1997;40:584–589

21. Nappo F, Esposito K, Ciolfi M, Giugliano G, Molinari AM, Paolisso G, Marfella R, Giugliano D. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002;39:1145–1150

22. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067–2072

23. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001;108:633–636

24. Williams SB, Goldfine AB, Timimi FK, Ting HH, Rody MA, Simonson DC, Creager MA. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695–1701

25. Khatri JJ, Johnson C, Magid R, Lessner SM, Laude KM, Dikalov SI, Harrison DG, Sung HJ, Rong Y, Galis ZS. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 2004;109:520–525

26. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 1999;99:2934–2941

27. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–820

28. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003;163:1306–1316

29. Piconi L, Quagliaro L, Da RR, Assaloni R, Giugliano D, Esposito K, Szabo C, Ceriello A. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004;2:1453–1459

30. Quagliaro L, Piconi L, Assaloni R, Martinielli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:2793–2804

31. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001;281:E924–E930

32. Nathan DM, Cleary PA, Backlund JY, Geenuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653

33. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonesca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Sittzle KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162–172